⚖️ NNMT Inhibitor

5-Amino-1MQ (50 mg Vial) Dosage Protocol

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule NNMT (nicotinamide N-methyltransferase) inhibitor. NNMT is an enzyme overexpressed in obese white adipose tissue that impairs cellular NAD+ availability and methionine cycle flux. Inhibiting NNMT reverses these metabolic impairments and reduces adipocyte size in preclinical models.

⚡ Quickstart Highlights

Reconstitution

Typically oral — dissolve in water or MCT oil

Daily Range

50–250 mg/day (oral)

Research Form

Oral powder or solution

Half-life

~3–6 hours

Dosing & Reconstitution Guide

Route: Oral (primary) or subcutaneous (research) | Frequency: Once or twice daily

Phase	Daily Dose	Notes
Weeks 1–2	50 mg/day	Starting dose; assess GI tolerance
Weeks 3–4	100 mg/day	Standard research range
Weeks 5–12	150–250 mg/day	Advanced protocols; from animal-derived mg/kg scaling

5-Amino-1MQ is typically used in oral form. It can be dissolved in a small volume of water or encapsulated. Unlike most peptides on this site, oral bioavailability is meaningful for this small molecule compound. No reconstitution with BAC water required for oral use.

Supplies Planning

Item	8 Weeks (100 mg/day)	12 Weeks (150 mg/day)
5-Amino-1MQ (50 mg vials/caps)	12 vials	26 vials
Method	Oral solution or capsule	Oral solution or capsule

Mechanism of Action

5-Amino-1MQ is a selective, cell-permeable inhibitor of NNMT (nicotinamide N-methyltransferase) — an enzyme that uses S-adenosylmethionine (SAM) to methylate nicotinamide, producing 1-methylnicotinamide (MNA) and S-adenosylhomocysteine (SAH). NNMT is overexpressed in obese white adipose tissue, where it acts as an epigenetic regulator that suppresses genes involved in fat burning while promoting fat storage.

By inhibiting NNMT, 5-Amino-1MQ preserves SAM methyl groups for other methylation reactions, improves NAD+ precursor availability, and upregulates genes involved in adipose tissue browning and energy expenditure. In mouse models, NNMT inhibition with related compounds reduced adipocyte size, lowered body fat without dietary changes, and improved metabolic markers including cholesterol and glucose tolerance.

Research Findings & Safety Profile

NNMT overexpressed in obese white adipose tissue; inhibition reduces adipocyte size in mouse models.
Improves NAD+ precursor availability and SAM methyl-donor capacity — downstream benefits for cellular energy metabolism.
Preclinical data: NNMT inhibition produces fat reduction without dietary restriction or adverse effects in mice.
Human clinical data is extremely limited as of 2025 — this is among the more experimental metabolic compounds.
Research grade compound; no human RCT data; all human dosing extrapolated from animal mg/kg scaling.
Possible effects largely unknown; GI tolerance should be assessed at low starting doses.

Storage

State	Temperature	Duration	Notes
Lyophilized	−20°C (−4°F)	Up to 24 months	Dry, dark conditions
Reconstituted	2–8°C (35–46°F)	Up to 60 days	Avoid freeze-thaw; protect from light

⚠ Research Use Only: 5-Amino-1MQ is among the most experimental metabolic compounds on this site — human clinical data is minimal. All human dosing extrapolated from animal models. Exercise appropriate caution.

References

Kannt A et al. 'Inhibition of nicotinamide N-methyltransferase NNMT as a novel strategy to treat fatty liver disease' — J Hepatol, 2018 View source ↗

Neelakantan H et al. 'Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high-fat diet-induced obesity' — Biochem Pharmacol, 2018 View source ↗